Actively Recruiting
Evaluating Safety and Effectiveness of HB-1 Tablets Compared to Placebo for Adults with Post-Traumatic Stress Disorder in a Randomized Double-Blind Study
Led by HB BioTech, LLC · Updated on 2026-09-24
200
Participants Needed
16
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of HB-1 compared to a placebo in adults aged 18 to 65 years diagnosed with Post-Traumatic Stress Disorder PTSD. This phase 2, multi-center, randomized, double-blind, placebo-controlled trial will include approximately 200 to 500 participants without severe neuropsychiatric or medical conditions. The study aims to better understand how HB-1 affects PTSD symptoms using established clinical assessments. Participants will receive HB-1, a dual active pharmaceutical ingredient tablet containing telmisartan and verapamil extended release, or a matching placebo. They will start with a lower dose of HB-1 taken once daily and may have their dose increased at Week 4 or Week 8 if symptoms have not sufficiently improved and no serious side effects have occurred. Treatment will continue for 12 weeks, followed by a safety follow-up one week after the last dose. Throughout the study, participants will attend visits at baseline, Week 4, Week 8, and Week 12 for symptom assessments using several clinical scales and questionnaires. Safety monitoring will include checking for adverse events, vital signs, ECGs, and lab tests. The primary outcome is the change in clinician-rated PTSD symptoms. The total participation time is about 13 weeks including treatment and follow-up.
CONDITIONS
Brief Title
Safety and Efficacy of HB-1 for Post-Traumatic Stress Disorder
Research Team
K
Karen Smith
A
Alon Seifan
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here